Calcium Glubionate (oral)

Calcium glubionate is an oral calcium supplement that provides elemental calcium in a highly bioavailable liquid form, making it particularly useful for reptile patients requiring calcium supplementation. This medication combines calcium with gluconic acid and boric acid to create a palatable syrup formulation that can be administered directly into the mouth or mixed with food items. The liquid formulation offers significant advantages in reptile medicine, as it allows for precise dosing in animals of varying sizes and facilitates administration to patients that may be reluctant to consume powdered calcium supplements. Calcium glubionate has become a valuable tool in the management of metabolic bone disease and other calcium deficiency conditions in captive reptiles.

The development and use of calcium glubionate in veterinary medicine represents an adaptation of human pharmaceutical products for exotic animal care. Originally formulated for human patients requiring oral calcium supplementation, this medication has found widespread extra-label application in reptile medicine due to its favorable characteristics. The syrup formulation provides approximately ninety milligrams of elemental calcium per five milliliters, though exact concentrations may vary between manufacturers. Reptile veterinarians have incorporated calcium glubionate into treatment protocols for metabolic bone disease, recognizing its value in providing supplemental calcium while addressing the underlying husbandry deficiencies that contribute to this common condition.

Calcium glubionate is available as an over-the-counter medication in most jurisdictions, making it accessible to reptile owners for use under veterinary guidance. The liquid syrup formulation typically comes in bottles of various sizes, with some veterinary compounding pharmacies preparing specialized concentrations or flavored versions for exotic animal use. Despite its over-the-counter availability, veterinary consultation is essential before initiating calcium glubionate supplementation in reptiles, as inappropriate use can contribute to imbalances in calcium and phosphorus metabolism. The veterinarian can provide guidance on appropriate dosing, duration of treatment, and integration with other aspects of metabolic bone disease management.

The effectiveness of calcium glubionate in reptile medicine depends on proper use as part of a comprehensive approach to calcium metabolism disorders. While this medication provides readily absorbable calcium, it cannot compensate for fundamental deficiencies in husbandry such as inadequate ultraviolet B lighting, inappropriate temperatures, or imbalanced diets. Calcium absorption from the gastrointestinal tract requires adequate vitamin D3, which reptiles obtain through either dietary supplementation or synthesis in the skin upon exposure to appropriate ultraviolet light. Therefore, calcium glubionate therapy must be integrated with corrections to environmental and dietary factors to achieve optimal outcomes in reptile patients with metabolic bone disease.

The primary indication for calcium glubionate in reptile medicine involves supportive treatment of metabolic bone disease, the most common calcium disorder affecting captive reptiles. Metabolic bone disease encompasses a spectrum of conditions resulting from calcium deficiency, phosphorus excess, vitamin D3 inadequacy, or combinations of these factors. Reptiles with MBD may present with soft or deformed bones, pathological fractures, muscle tremors, weakness, difficulty walking, and in severe cases, seizures due to hypocalcemia. Calcium glubionate provides supplemental calcium to help restore blood calcium levels and support bone remineralization while underlying husbandry problems are corrected. The liquid formulation is particularly valuable for reptiles too weak to consume normal food items dusted with powdered calcium.

Lizard species commonly receive calcium glubionate as part of metabolic bone disease management, with bearded dragons, leopard geckos, and iguanas representing frequently affected species. Young, rapidly growing lizards are particularly susceptible to MBD due to their high calcium demands for skeletal development. Calcium glubionate can be administered directly into the mouth of affected lizards using a small syringe, allowing for precise dosing and ensuring the animal receives the full intended amount. For lizards with mild disease that are still eating, the syrup can sometimes be drizzled onto food items, though direct oral administration provides more reliable dosing. Chameleons, with their sensitivity to handling stress and precise supplementation requirements, may benefit from calcium glubionate under careful veterinary supervision.

Chelonian species including turtles and tortoises frequently require calcium supplementation for metabolic bone disease management. Shell deformities, soft shells, and pyramiding in tortoises often reflect chronic calcium and vitamin D3 deficiencies that have developed over months or years of inadequate husbandry. Calcium glubionate provides supplemental calcium support while dietary and environmental corrections take effect. Aquatic turtle species such as red-eared sliders may develop MBD when maintained on inappropriate diets or without adequate access to basking areas and ultraviolet light. The palatable liquid formulation can be administered orally with careful technique to ensure the animal swallows the medication rather than aspirating it.

Beyond metabolic bone disease treatment, calcium glubionate may be indicated for reproductive support in female reptiles. Egg-laying species have significantly increased calcium demands during follicle development and shell formation. Female reptiles experiencing egg-binding or dystocia may have concurrent hypocalcemia contributing to uterine muscle weakness. Supplemental calcium, often in combination with other supportive measures, can help support uterine contractions and egg passage. Similarly, reproductively active female reptiles may receive prophylactic calcium supplementation during breeding season to support healthy egg development and prevent calcium depletion.

Calcium glubionate may also be indicated for acute hypocalcemia management in reptiles when intravenous or intramuscular calcium administration is not immediately available or practical. While injectable calcium gluconate remains the preferred treatment for severe acute hypocalcemia and tetany, oral calcium glubionate can provide interim support in less critical situations or during the transition from injectable to oral supplementation. The veterinarian will determine the appropriate treatment approach based on the severity of hypocalcemia, the patient's clinical status, and available resources. Oral calcium supplementation is not appropriate for life-threatening hypocalcemic tetany, which requires immediate injectable calcium therapy.

Dosing of calcium glubionate in reptiles requires veterinary determination based on the individual patient's species, body weight, clinical condition, and severity of calcium deficiency. No standardized dosing protocols exist for reptiles, as this medication is used entirely on an extra-label basis in these species. Veterinary dose recommendations are derived from clinical experience, pharmacological principles, and extrapolation from available literature. The reptile veterinarian will calculate an appropriate dose based on the patient's needs and provide specific instructions for administration frequency and duration. Owners should follow veterinary guidance precisely and should not adjust doses without consultation, as both underdosing and overdosing can have adverse consequences.

Temperature considerations significantly impact calcium absorption and metabolism in reptile patients receiving oral calcium glubionate. Reptiles maintained at appropriate temperatures within their preferred optimum temperature zone will have optimal gastrointestinal function, including efficient calcium absorption from the intestinal tract. Cold reptiles experience slowed digestive processes, which may reduce calcium absorption and delay therapeutic effects. Additionally, vitamin D3, which is essential for intestinal calcium absorption, is metabolized more efficiently at appropriate temperatures. The veterinarian will emphasize maintaining proper thermal gradients during treatment, potentially recommending temperatures at the higher end of the species' preferred range to support recovery.

Oral administration of calcium glubionate requires careful technique to ensure effective delivery while minimizing stress and aspiration risk. The medication is typically administered using a small syringe without a needle, with the tip gently inserted into the side of the mouth while the reptile's head is held in a natural or slightly elevated position. The syrup should be delivered slowly, allowing the animal time to swallow between small amounts. Rushing administration or forcing large volumes risks aspiration into the respiratory tract, which can cause serious pneumonia. For small reptiles such as juvenile geckos, extremely small syringes or diluted preparations may be necessary to allow accurate measurement of tiny doses.

The frequency of calcium glubionate administration varies based on clinical circumstances and veterinary recommendations. Acute management of symptomatic hypocalcemia may require more frequent dosing initially, potentially multiple times daily, to restore calcium levels. Maintenance supplementation for ongoing MBD management typically involves less frequent administration, often once daily or every other day. Long-term prophylactic supplementation during high-demand periods such as breeding season may follow yet another schedule. Treatment duration depends on resolution of clinical signs, improvement in blood calcium levels, and successful correction of underlying husbandry deficiencies. The veterinarian will provide guidance on tapering or discontinuing supplementation as the patient improves.

Species-specific administration considerations influence how calcium glubionate is delivered to different reptile types. Most lizards accept oral medication reasonably well when handled gently and given time to swallow between doses. Bearded dragons and iguanas often tolerate oral medication with minimal restraint needed. Geckos and smaller lizards require delicate handling and precise dosing. Chelonians may retract into their shells during administration attempts, requiring patience and possibly gentle manipulation to expose the head for medication delivery. Some tortoises and turtles accept flavored medications more readily if they associate the taste with food. Snakes rarely receive oral calcium glubionate due to their unique physiology and feeding patterns.

Owner administration of calcium glubionate at home is common following veterinary instruction, as the oral route is more accessible for owners than injectable medications. The veterinarian or veterinary staff should demonstrate proper technique, including appropriate restraint, positioning, syringe handling, and pacing of administration. Owners should practice under supervision before independent home administration. Recording each dose helps ensure consistent treatment and provides information for veterinary follow-up appointments. Any difficulties with administration, including apparent refusal or regurgitation, should be reported to the veterinarian, who may suggest alternative approaches or reassess the treatment plan.

Calcium glubionate administered appropriately under veterinary guidance is generally well-tolerated by reptile patients, though potential side effects can occur. The most significant concern involves hypercalcemia, which can develop if calcium supplementation is excessive relative to the animal's needs. Signs of hypercalcemia in reptiles may include lethargy, weakness, anorexia, increased thirst and urination, constipation, and in severe cases, soft tissue mineralization or kidney damage. This risk underscores the importance of veterinary oversight during calcium supplementation and the need to address underlying husbandry issues rather than relying solely on medication to manage calcium balance. Regular monitoring of blood calcium levels helps detect developing hypercalcemia before serious complications occur.

Temperature-related effects can influence how reptiles respond to oral calcium glubionate supplementation. Reptiles maintained below their preferred optimum temperature zone may experience reduced intestinal absorption of calcium, diminishing the effectiveness of supplementation. Paradoxically, if environmental temperatures then increase significantly, previously unabsorbed calcium may suddenly become available, potentially causing rapid changes in blood calcium levels. Maintaining stable, appropriate temperatures throughout treatment supports predictable calcium absorption and reduces the risk of fluctuations that could cause adverse effects. Owners should monitor enclosure temperatures carefully during the treatment period.

Gastrointestinal disturbances represent relatively common side effects of oral calcium glubionate administration in some reptiles. The syrup formulation contains sugars and other ingredients that may cause mild digestive upset in sensitive individuals. Potential gastrointestinal effects include loose stools or diarrhea, decreased appetite, or visible abdominal discomfort. These effects are typically mild and often resolve as the animal adjusts to the medication or when dosing is completed. Administering calcium glubionate with or shortly after meals may help reduce gastrointestinal irritation in some cases. Significant or persistent gastrointestinal problems warrant veterinary consultation to rule out other causes and potentially adjust the treatment approach.

Aspiration represents a serious potential complication of oral medication administration in reptiles, though careful technique minimizes this risk. If liquid calcium glubionate enters the respiratory tract rather than the digestive system, aspiration pneumonia can develop. Signs of aspiration may include open-mouth breathing, crackling respiratory sounds, nasal discharge, lethargy, and anorexia developing within hours to days after medication administration. Proper positioning during administration, slow delivery of small volumes, and allowing adequate swallowing time between doses significantly reduce aspiration risk. Any suspected aspiration requires immediate veterinary evaluation.

Owners should contact their reptile veterinarian if any concerning changes occur during calcium glubionate treatment. Signs warranting veterinary attention include persistent lethargy or weakness, complete refusal to eat for more than a few days, respiratory difficulties or abnormal breathing sounds, significant changes in urination or defecation patterns, muscle tremors or tetany despite supplementation, or any sudden changes in behavior or condition. While many mild side effects resolve spontaneously, prompt reporting of concerns allows the veterinarian to assess whether the treatment plan needs modification and to identify potential complications early when intervention is most effective.

Calcium glubionate supplementation is contraindicated in reptiles with documented hypercalcemia, as additional calcium administration would exacerbate this dangerous condition. Hypercalcemia in reptiles can result from various causes including excessive supplementation, vitamin D toxicosis, certain cancers producing parathyroid hormone-related peptide, and some kidney diseases. Before initiating calcium supplementation, veterinarians should ideally assess blood calcium levels to confirm hypocalcemia or at least evaluate clinical signs consistent with calcium deficiency. Empirical calcium supplementation without diagnostic confirmation risks worsening hypercalcemia if this condition is actually present. Reptiles with known hypercalcemia require treatment directed at reducing calcium levels rather than supplementation.

Reptiles with known or suspected renal disease require careful evaluation before calcium glubionate therapy is initiated. The kidneys play an essential role in calcium homeostasis, regulating calcium excretion and contributing to vitamin D activation. Impaired kidney function can alter calcium handling in unpredictable ways, potentially leading to hypercalcemia despite apparent calcium deficiency symptoms or causing rapid fluctuations in calcium levels. Reptiles with kidney disease may need modified supplementation protocols, enhanced monitoring, or alternative approaches to calcium management. The veterinarian will consider renal function status when developing treatment plans for reptiles with calcium disorders.

Hypersensitivity to any component of calcium glubionate formulations represents a contraindication to its use. While true allergic reactions to calcium supplements appear rare, the syrup formulation contains various inactive ingredients including sweeteners, preservatives, and flavorings that could potentially cause adverse reactions in sensitive individuals. Any reptile that has previously experienced unusual reactions following calcium glubionate administration should not receive the medication again without careful veterinary evaluation. Signs of potential hypersensitivity might include unusual swelling, gastrointestinal distress disproportionate to the dose given, or systemic signs following administration.

Calcium glubionate should not be considered a substitute for comprehensive management of metabolic bone disease and calcium metabolism disorders. Using calcium supplements alone without addressing fundamental husbandry deficiencies represents inappropriate medical management that will ultimately fail to resolve the underlying problem. Essential concurrent interventions include providing appropriate ultraviolet B lighting exposure to enable vitamin D3 synthesis, maintaining proper temperature gradients to support metabolism, correcting dietary calcium-to-phosphorus ratios, and ensuring overall nutritional adequacy. Veterinary consultation is essential to develop a complete treatment plan, and calcium glubionate should be viewed as one component of multimodal therapy rather than a standalone solution.

Calcium glubionate can interact with various other substances that affect calcium absorption, metabolism, or excretion, requiring consideration when combination therapies are employed. Phosphorus-containing supplements or high-phosphorus foods can interfere with calcium absorption from the gastrointestinal tract, as phosphorus and calcium compete for absorption and form insoluble complexes that reduce bioavailability of both minerals. Diets with inappropriate calcium-to-phosphorus ratios represent a common underlying cause of metabolic bone disease, and concurrent phosphorus supplementation during calcium glubionate therapy would counteract treatment benefits. Veterinarians typically recommend dietary modifications to optimize calcium-to-phosphorus ratios alongside calcium supplementation.

Interactions between calcium glubionate and vitamin D3 supplements require careful management. Vitamin D3 enhances intestinal calcium absorption, and the combination of vitamin D3 supplementation with oral calcium can significantly increase calcium bioavailability. While this interaction is often therapeutically beneficial for treating metabolic bone disease, excessive combined supplementation can lead to hypercalcemia and hypervitaminosis D. The veterinarian will coordinate calcium and vitamin D3 supplementation to achieve optimal calcium status without risking toxicity. Monitoring blood calcium levels helps guide appropriate dosing of both supplements.

Certain medications commonly used in reptile medicine may interact with calcium supplements or affect calcium metabolism. Corticosteroids, sometimes prescribed for inflammatory conditions, can affect calcium homeostasis through various mechanisms and may alter the effectiveness of calcium supplementation. Some antibiotics, particularly fluoroquinolones, can form complexes with calcium that reduce absorption of both the antibiotic and the calcium supplement; separation of administration times may be recommended when these medications are used concurrently. Antacids and other medications affecting gastric pH may influence calcium absorption. The veterinarian should be informed of all medications and supplements the reptile receives to assess potential interactions.

Generally safe combinations with calcium glubionate include most antibiotics commonly prescribed for reptile infections, antiparasitic medications, and supportive care products that do not directly affect calcium metabolism. Concurrent treatment of infections or parasites in a reptile with metabolic bone disease is common and does not typically require modification of the calcium supplementation protocol. Fluid therapy for hydration support is compatible with oral calcium supplementation. Liver support supplements and probiotics used in reptile medicine do not have significant interactions with calcium glubionate. As always, informing the veterinarian of all treatments helps ensure safe and effective combination therapy.

Temperature maintenance during calcium glubionate treatment is essential for optimizing calcium absorption and therapeutic outcomes. Reptiles must be maintained within their species-specific preferred optimum temperature zone to ensure proper gastrointestinal function and calcium absorption. Cold temperatures slow digestive processes and reduce the efficiency of nutrient absorption from the intestinal tract. Additionally, vitamin D3 metabolism, which is critical for calcium absorption, depends on appropriate body temperatures. Owners should verify that heating equipment is functioning correctly and that appropriate thermal gradients exist in the enclosure throughout the treatment period. The veterinarian may recommend maintaining temperatures at the higher end of the preferred range for sick reptiles requiring enhanced metabolic support.

Proper administration technique prevents aspiration and ensures effective delivery of calcium glubionate. Oral medications must be given carefully to avoid introduction of liquid into the respiratory tract, which can cause aspiration pneumonia. The reptile should be positioned with its head in a natural or slightly elevated position, never tilted back in a way that would direct liquid toward the glottis. Small volumes should be administered slowly, with pauses to allow swallowing between doses. If the animal shows signs of choking, coughing, or struggle, administration should stop immediately. Owners uncomfortable with oral medication administration should seek additional training from veterinary staff or request alternative treatment approaches.

Monitoring for signs of hypercalcemia is important during calcium supplementation, particularly with prolonged treatment or higher doses. While metabolic bone disease typically involves calcium deficiency, overzealous supplementation can cause calcium levels to rise excessively. Signs of hypercalcemia include lethargy, weakness, loss of appetite, increased urination, and constipation. Severe hypercalcemia can cause soft tissue mineralization, kidney damage, and other serious complications. Regular veterinary rechecks, including blood calcium monitoring when indicated, help ensure calcium levels remain within appropriate ranges throughout treatment. Owners should report any concerning signs promptly.

Addressing underlying husbandry deficiencies alongside calcium supplementation is essential for successful treatment outcomes. Calcium glubionate provides supplemental calcium but cannot compensate for fundamental environmental and dietary problems that cause metabolic bone disease. Ultraviolet B lighting must be evaluated and corrected if inadequate, as UVB exposure enables reptiles to synthesize vitamin D3 in their skin, which is essential for intestinal calcium absorption. Temperature gradients must support proper thermoregulation. Diet composition should be assessed to ensure appropriate calcium content and calcium-to-phosphorus ratios. Without these corrections, calcium supplementation provides temporary support at best and will not resolve metabolic bone disease long-term.

Human safety considerations for calcium glubionate are minimal, as this is an oral supplement with low toxicity. Standard hygiene practices apply, including hand washing after handling the medication and any associated equipment. The medication should be stored out of reach of children, who might be attracted to the sweet syrup formulation. While accidental ingestion of small amounts by humans is unlikely to cause harm, the product is intended for the reptile patient only. Proper storage prevents degradation and maintains effectiveness throughout the treatment course. Disposing of unused or expired medication appropriately protects household members and the environment.

Calcium glubionate oral syrup should be stored according to manufacturer recommendations, typically at controlled room temperature away from excessive heat, light, and moisture. Most formulations remain stable when stored between 15°C and 30°C (59°F to 86°F), though specific products may have different requirements as noted on their packaging. Refrigeration is generally not required for calcium glubionate syrup and may cause the product to thicken or crystallize, potentially affecting accurate dosing. However, some owners prefer refrigeration for palatability reasons, which is acceptable if the product label does not prohibit it. The medication should be kept in its original container with the cap tightly closed to prevent evaporation and contamination.

Once opened, the shelf life of calcium glubionate syrup depends on the specific product formulation and storage conditions. Most oral syrups remain stable for several months after opening when stored properly, though potency may gradually decrease over time. Following the manufacturer's guidance regarding use-by dates after opening ensures optimal effectiveness. Any changes in color, consistency, or odor may indicate degradation, and products showing such changes should be discarded. Using measuring devices that contact the syrup, such as oral syringes, introduces potential for contamination; using clean syringes and avoiding contact between the syringe tip and other surfaces helps maintain product integrity.

Safe handling and disposal practices for calcium glubionate are straightforward given its relatively benign nature. The medication should be kept away from children and household pets to prevent accidental ingestion of large amounts. While the sweet taste makes the product palatable for administration to reptiles, it could also be attractive to curious children or animals. Disposal of unused or expired medication should follow local guidelines for pharmaceutical waste. Many communities have medication take-back programs, and pharmacies may accept returns of unused veterinary medications. Flushing or pouring the syrup down drains is not recommended due to environmental concerns. The original container can typically be recycled after thorough rinsing.

Lizard species represent the most common recipients of calcium glubionate therapy due to the high prevalence of metabolic bone disease in captive lizards, particularly popular pet species kept by inexperienced owners. Bearded dragons rank among the most frequently affected species and respond well to calcium supplementation as part of comprehensive MBD treatment. Their moderate size and generally calm temperament facilitate oral medication administration. Leopard geckos and other small gecko species require careful attention to dosing accuracy, as their small body size means even small volume errors significantly impact the dose received. Chameleons present particular challenges due to their sensitivity to stress and handling; minimizing restraint time while ensuring accurate medication delivery requires experienced technique. Larger lizards such as iguanas and monitors may receive calcium glubionate when indicated, with doses scaled appropriately for their body size.

Chelonian species including both aquatic turtles and terrestrial tortoises frequently require calcium supplementation for metabolic bone disease and shell abnormalities. Tortoises, especially popular species like Russian tortoises, red-footed tortoises, and sulcata tortoises, commonly develop MBD-related shell deformities when maintained under suboptimal conditions. Oral calcium glubionate can be administered to tortoises when they extend from their shells, though patience may be required with shy individuals. Aquatic turtles such as red-eared sliders and painted turtles may receive calcium supplementation for soft shell conditions, though administration requires careful technique to prevent aspiration, particularly in species adapted to consuming food underwater. Semi-aquatic species like box turtles tolerate oral medication similarly to terrestrial chelonians.

Temperature requirements for optimal calcium absorption and metabolism vary among reptile species and must be maintained during treatment. Desert-dwelling species such as bearded dragons require basking spots reaching approximately 38-43°C (100-110°F) with cooler zones available for thermoregulation. Tropical species like green iguanas require higher ambient humidity alongside appropriate temperatures. Leopard geckos and other crepuscular species may utilize belly heat rather than overhead basking, requiring appropriate under-tank heating. Chelonians have species-specific temperature requirements, with tropical species generally requiring warmer conditions than temperate species. Maintaining these appropriate thermal conditions supports proper digestion, calcium absorption, and overall metabolic function during treatment.

Size considerations significantly influence calcium glubionate dosing and administration across reptile species. Hatchling and juvenile reptiles require very small volumes that necessitate careful measurement, potentially using tuberculin syringes or diluted preparations to allow accurate dosing. Large adult reptiles such as mature iguanas or sulcata tortoises require proportionally larger doses scaled to body weight. The veterinarian calculates appropriate doses considering species-specific factors, individual body size, severity of calcium deficiency, and concurrent treatments. Regardless of patient size, proper administration technique remains essential to ensure the animal receives the full dose without aspiration risk.

Within the category of oral calcium supplements for reptiles, several alternatives to calcium glubionate exist with varying characteristics. Calcium carbonate powder represents the most common form of calcium supplementation for reptiles, typically applied to food items as a dusting. While effective for maintenance supplementation in healthy reptiles, powdered calcium is less suitable for sick animals that are not eating or for situations requiring precise dosing. Calcium citrate provides an alternative salt form with good bioavailability that some reptiles may accept better than other forms. Calcium lactate and calcium gluconate are also available as oral supplements with varying absorption characteristics. The veterinarian will recommend the most appropriate calcium formulation based on the patient's specific needs and circumstances.

Injectable calcium preparations serve different therapeutic purposes than oral calcium supplements and may be used in combination or as alternatives depending on clinical circumstances. Calcium gluconate injection provides rapid calcium supplementation for reptiles with severe hypocalcemia or tetanic seizures, situations where oral supplementation would be inadequate. Injectable calcium is administered intravenously or intramuscularly by veterinary professionals for acute management, with oral supplementation typically following for ongoing support. The transition from injectable to oral calcium supplementation represents a common treatment progression as reptiles recover from acute hypocalcemia and begin eating normally.

Comprehensive metabolic bone disease management typically involves combination therapy approaches beyond calcium supplementation alone. Vitamin D3 supplementation supports calcium absorption and may be provided orally or through proper ultraviolet B lighting exposure. Phosphorus reduction through dietary modification complements calcium supplementation by improving calcium-to-phosphorus ratios. Calcitonin may be indicated in rare cases of hypercalcemia to reduce elevated calcium levels. Beyond pharmaceutical interventions, husbandry corrections including proper lighting, temperature, and nutrition form the foundation of successful MBD treatment. The veterinarian coordinates all aspects of therapy to provide comprehensive care for reptiles with calcium metabolism disorders.